Oxaliplatine Accord

Oxaliplatin, the active ingredient in Oxaliplatine Accord, is a platinum‑based antineoplastic agent presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, including metastatic disease, primarily in adult patients undergoing chemotherapy regimens.

GNH USA supplies Oxaliplatine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑controlled distribution and regulatory compliance across global markets. The company adheres to stringent quality standards, providing reliable supply chains and supporting clinical teams with product information and technical assistance.

Oxaliplatin is used in chemotherapy protocols targeting colorectal malignancies and related disease stages. - Colorectal cancer: Improves response rates and survival when combined with fluoropyrimidines. - Metastatic colorectal cancer: Provides disease control in advanced cases as part of combination regimens. - Adjuvant treatment of stage III colon cancer: Reduces recurrence risk after surgical resection.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: Gastrointestinal upset occurring during or after infusion. - Peripheral neuropathy: Tingling or numbness, often dose‑related. - Fatigue: Generalized tiredness affecting daily activities. - Neutropenia: Reduced white blood cell count increasing infection risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm requiring immediate medical attention. - Pulmonary toxicity: Interstitial lung disease presenting with dyspnea. - Thrombocytopenia: Marked platelet drop leading to bleeding complications.

Prior to initiating therapy, clinicians should assess baseline health status and monitor for specific risks. - Monitor blood counts: Regular CBC to detect neutropenia, anemia, or thrombocytopenia. - Assess renal function: Adjust therapy if creatinine clearance is reduced. - Evaluate for neuropathy: Discontinue or dose‑reduce if severe peripheral neuropathy develops. - Contraindicated in pregnancy: Avoid use due to unknown fetal risk. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concurrent platinum agents: Increases cumulative toxicity. - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): Heightens renal injury risk. - Live vaccines: May cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): Monitor coagulation parameters. - CYP450 inducers (rifampin, carbamazepine): May alter drug clearance. - NSAIDs: Watch for additive gastrointestinal toxicity.